About 100 reports

Zentiva' s key product groups include anti-infection products and medicines for cardiovascular disease, pain, central nervous system disorders, female healthcare and gastrointestinal diseases.

  • Gastrointestinal Drug
  • Healthcare
  • Romania
  • Demand
  • Zentiva NV
  • DIGESTIVE REMEDIES IN RUSSIA - CATEGORY ANALYSIS

Doctors also significantly contributed to the growth of microgranules by prescribing them to people with gastrointestinal problems.

  • Gastrointestinal Drug
  • OTC
  • Russian Federation
  • Demand
  • Consumer Lifestyles Fuel Demand for Digestive Remedies

Stress can cause and exacerbate numerous digestive disorders, including nausea, indigestion and heartburn, as well as general gastrointestinal upset.

  • Gastrointestinal Drug
  • OTC
  • United States
  • Demand

SUMMARY: - Gastrointestinal Disorders Pipeline by Indication - Gastrointestinal Disorders Pipeline by Clinical Trial Phase - Gastrointestinal Disorders Pipeline by Drug Mechanism Classes - Gastrointestinal Disorders Pipeline by Company

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pathology

Moreover, vitamins and dietary supplements must not be advertised for any specific medicinal purpose, such as cardiovascular or gastrointestinal disease.

  • Gastrointestinal Drug
  • OTC
  • Singapore
  • Demand
  • DIGESTIVE REMEDIES IN THE US - CATEGORY ANALYSIS

Stress can cause and exacerbate numerous digestive disorders, including nausea, indigestion and heartburn, as well as general gastrointestinal upset.

  • Allergy Drug
  • Gastrointestinal Drug
  • OTC
  • United States
  • Demand
  • TRENDS

In addition, stressful and fast-paced lifestyles, with tight schedules and traffic jams, impact the digestive system, causing tension, which is reflected in gastrointestinal discomfort.

  • Gastrointestinal Drug
  • OTC
  • Colombia
  • Demand
  • Tecnoquímicas SA

Zentiva' s key product groups include anti-infection products and medicines for cardiovascular disease, pain, central nervous system disorders, female healthcare and gastrointestinal diseases.

  • Gastrointestinal Drug
  • Healthcare
  • Romania
  • Demand
  • Zentiva NV
  • Clinical Trial profile. 17 Trial Title
  • Target

PROPORTION OF BARRETTS ESOPHAGUS TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF BARRETTS ESOPHAGUS TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* AS OF APRIL 2017, THERE WERE ## CLINICAL TRIALS IN PHASE II, OF WHICH THREE CLINICAL TRIALS WE

  • Gastrointestinal Drug
  • Hospital
  • Therapy
  • World
  • Product Initiative
  • PROPORTION OF INFECTIOUS DIARRHEA TO GASTROINTESTINAL CLINICAL TRIALS, E7 COUNTRIES (%), 2017*
  • PROPORTION OF INFECTIOUS DIARRHEA TO GASTROINTESTINAL CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pathology
  • World
  • Product Initiative
  • Clinical Trial profile. 5 Trial Title
  • CLINICAL TRIAL PROFILE SNAPSHOTS

PROPORTION OF CORROSIVE ESOPHAGITIS (EROSIVE ESOPHAGITIS) TO GASTROINTESTINAL CLINICAL TRIALS, G## COUNTRIES (%), 2017* PROPORTION OF CORROSIVE ESOPHAGITIS (EROSIVE ESOPHAGITIS) TO GASTROINTESTINAL CLINICAL TRIALS, G## COUNTRIES (%), 2017* In total there were ## clinical trials condu

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Therapy
  • World
  • Takeda Pharmaceutical Company Limited
  • FECAL INCONTINENCE THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2017*
  • Clinical Trial profile. 38 Trial Title

PROPORTION OF FECAL INCONTINENCE TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF FECAL INCONTINENCE TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF FECAL INCONTINENCE TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%

  • Gastrointestinal Drug
  • Therapy
  • World
  • Product Initiative
  • RDD Pharma
  • Clinical Trial profile. 99 Trial Title
  • Clinical Trial profile. 177 Trial Title

PROPORTION OF DUODENAL ULCER TO GASTROINTESTINAL CLINICAL TRIALS, G## COUNTRIES (%), 2017* PROPORTION OF DUODENAL ULCER TO GASTROINTESTINAL CLINICAL TRIALS, G## COUNTRIES (%), 2017* In total there were ## clinical trials conducted on Duodenal Ulcer, as of July 2017 in G## Countries, o

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • World
  • Product Initiative
  • NANOTHERAPEUTICS INC
  • FEATURED NEWS & PRESS RELEASES

IBS is one of the most common gastrointestinal disorders.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Product Initiative
  • RedHill Biopharma Ltd.
  • Clinical Trial profile. 301 Trial Title
  • Target

Upper gastrointestinal endoscopy will be performed prior to drug treatment, and at the end of the ##-day study period.

  • Drug Discovery And Development
  • Gastrointestinal Drug
  • World
  • Product Initiative
  • AstraZeneca PLC
  • Clinical Trials by G7 Countries: Proportion of Acid Indigestion / Heartburn/ Pyrosis to Gastrointestinal Clinical Trials
  • Clinical Trials by E7 Countries: Proportion of Acid Indigestion / Heartburn/ Pyrosis to Gastrointestinal Clinical Trials
  • Digestive System Disorder
  • Gastrointestinal Drug
  • OTC
  • World
  • Product Initiative
  • Clinical Trial profile. 846 Trial Title
  • Target

PROPORTION OF ESOPHAGEAL DISEASES TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF ESOPHAGEAL DISEASES TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* IN TOTAL THERE WERE ## CLINICAL TRIALS CONDUCTED ON ESOPHAGEAL DISEASES, AS OF AUGUST 2017

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • World
  • Official Title
  • Official Title

PROPORTION OF DYSPEPSIA TO GASTROINTESTINAL CLINICAL TRIALS, G## COUNTRIES (%), 2017* Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials are taken for a time period of 1995 - 2017 2017 trials are taken as of July 2017 PROPORTION OF DYSPEPSIA TO

  • Clinical Trial
  • Drug Discovery And Development
  • Gastrointestinal Drug
  • World
  • Yt Blood Group
  • Clinical Trial profile. 35 Trial Title
  • Clinical Trial profile. 161 Trial Title

PROPORTION OF EMESIS (VOMITING) TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF EMESIS (VOMITING) TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF EMESIS (VOMITING) TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%),

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • World
  • Product Initiative
  • Clinical Trial profile. 920 Trial Title
  • Clinical Trial profile. 948 Trial Title

ESOPHAGITIS THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY TRIAL STATUS, 2017* CLINICAL TRIALS BY E## COUNTRIES: PROPORTION OF ESOPHAGITIS TO GASTROINTESTINAL CLINICAL TRIALS AMONG THE E## (BRAZIL, RUSSIA, INDIA, CHINA, MEXICO, TURKEY AND INDONESIA) COUNTRIES, BRAZIL HAVE THE HIGHEST PROPORTI

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • World
  • Official Title

PROPORTION OF FUNCTIONAL (NON ULCER) DYSPEPSIA TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF FUNCTIONAL (NON ULCER) DYSPEPSIA TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF FUNCTIONAL (NON ULCER) DYSPEPSIA TO

  • Gastrointestinal Drug
  • Pharmaceutical
  • World
  • Product Initiative
  • Yt Blood Group
  • Clinical Trials by E7 Countries: Proportion of Acid Indigestion / Heartburn/ Pyrosis to Gastrointestinal Clinical Trials
  • Clinical Trials by G7 Countries: Proportion of Acid Indigestion / Heartburn/ Pyrosis to Gastrointestinal Clinical Trials
  • Digestive System Disorder
  • Gastrointestinal Drug
  • OTC
  • World
  • Product Initiative
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF IRRITABLE BOWEL SYNDROME TO GASTROINTESTINAL CLINICAL TRIALS
  • PROPORTION OF IRRITABLE BOWEL SYNDROME TO GASTROINTESTINAL CLINICAL TRIALS, E7 COUNTRIES (%), 2017*
  • Digestive System Disorder
  • Drug Discovery And Development
  • Gastrointestinal Drug
  • World
  • GlaxoSmithKline plc
  • Target
  • Clinical Trial profile. 21 Trial Title

PROPORTION OF ACIDITY TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF ACIDITY TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF ACIDITY TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* Source: GlobalData'

  • Gastrointestinal Drug
  • Therapy
  • World
  • Product Initiative
  • Bayer AG
  • Clinical Trial profile. 121 Trial Title
  • Clinical Trial profile. 46 Trial Title

Proportion of Zollinger-Ellison Syndrome (Gastrinoma) to Gastrointestinal Clinical Trials, E## Countries (%), 2016* Proportion of Zollinger-Ellison Syndrome (Gastrinoma) to Gastrointestinal Clinical Trials, E## Countries (%), 2016* Proportion of Zollinger-Ellison Syndrome (Gastrinoma

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Hospital
  • World
  • Product Initiative
  • MICROCAM NAVI - UPPER GASTROINTESTINAL DISORDERS - PRODUCT STATUS
  • MICROCAM NAVI - UPPER GASTROINTESTINAL DISORDERS - PRODUCT DESCRIPTION
  • Clinical Trial
  • Gastrointestinal Drug
  • United States
  • Company
  • GlobalData's company
  • Clinical Trial profile. 23 Trial Title
  • Target

Proportion of Nonerosive Reflux Disease (NERD) to Gastrointestinal Clinical Trials, E## Countries (%), 2016* Proportion of Nonerosive Reflux Disease (NERD) to Gastrointestinal Clinical Trials, E## Countries (%), 2016* Proportion of Nonerosive Reflux Disease (NERD) to

  • Digestive System Disorder
  • Gastrointestinal Drug
  • World
  • Product Initiative
  • Takeda Pharmaceutical Company Limited
  • PROPORTION OF DIARRHEA TO GASTROINTESTINAL CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • PROPORTION OF DIARRHEA TO GASTROINTESTINAL CLINICAL TRIALS, E7 COUNTRIES (%), 2017*
  • Gastrointestinal Drug
  • Opioid
  • Pharmaceutical
  • World
  • Product Initiative
  • PROPORTION OF CONSTIPATION TO GASTROINTESTINAL CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF CONSTIPATION TO GASTROINTESTINAL CLINICAL TRIALS
  • Drug Discovery And Development
  • Gastrointestinal Drug
  • World
  • Product Initiative
  • Braintree Laboratories Inc.
  • About the Phase III GUARD study
  • JAN 12, 2017: REDHILL BIOPHARMA PROVIDES MILESTONE UPDATE ON BEKINDA

IBS is one of the most common gastrointestinal disorders.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Product Initiative
  • RedHill Biopharma Ltd.